Current aproach to cancer pain management: Availability and implications of different treatment options

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 381-400

  Nersesyan, Hrachya ^a   Slavin, Konstantin V ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Adjuvant; Analgesic ladder; Neuromodulation; Opioids

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; CARBAMAZEPINE; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; GABAPENTIN; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; KETAMINE; MECLOFENAMIC ACID; MEFENAMIC ACID; METHADONE; MORPHINE; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFAMPICIN; ROFECOXIB; SULINDAC; TOLMETIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; CANCER PAIN; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELIAC PLEXUS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CORDOTOMY; DELIRIUM; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HALLUCINATION; HEMATOLOGIC DISEASE; HUMAN; HYPERVENTILATION; IMMUNE DEFICIENCY; INTRACTABLE PAIN; KIDNEY FAILURE; KYPHOPLASTY; LIBIDO DISORDER; LIVER DYSFUNCTION; LIVER TOXICITY; METABOLIC ACIDOSIS; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NERVE BLOCK; NEUROLYSIS; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPERTENSION; PAIN ASSESSMENT; PAIN THRESHOLD; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RESPIRATORY ARREST; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH HEMORRHAGE; STOMACH ULCER; SUBFERTILITY; SUSTAINED RELEASE PREPARATION; THALAMOTOMY; TINNITUS; UNSTEADINESS; URINE RETENTION; VERTIGO; VOMITING; XEROSTOMIA;

EID: 34547658885     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Ahmedzai S. 1997. New approaches to pain control in patients with cancer. Eur J Can, 33(Suppl 6):S8-14.
2. Ahmedzai S, Brooks D. 1997. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage, 13:254-61.
3. Alvarez V, Arttamangkul S, Williams JT. 2001. A RAVE about opioid withdrawal. Neuron, 32:761-63.
4. [ACS] American Cancer Society. 2002. Cancer facts and figures 2002 [online]. Accessed 4 April 2006. URL: http://www.cancer.org/docroot/STT/ STT_0.asp.
5. Arnold L, Lu Y, Crofford L, et al. 2004. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum, 50:2974-84.
6. Backonja MM. 2000. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain, 16(Suppl 6):67-72.
7. Balducci L. 2003. Management of cancer pain in geriatric patients. J Support Oncol, 1: 175-91.
8. Ballantyne JC, Mao J. 2003. Opioid therapy for chronic pain. N Engl J Med, 349:1943-53.
9. Becker R, Jakob D, Uhle E, et al. 2000. The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosurg, 75:16-26.
10. Bedder MD, Burchiel K, Larson A. 1991. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage, 6:368-73.
11. Benedetti C, Brock C, Cleeland C, et al. 2000. NCCN practice guidelines for cancer pain. Oncology, 14:135-50.
12. Berland D. 2000. Pain management in patients with advanced cancer. Ann Intern Med, 132:593.
13. Bloodworth D. 2005. Issues in opioid management. Am J Phys Med Rehabil, 84(Suppl 3):S42-55.
14. Bombardier C, Laine L, Reicin A, et al. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Eng J Med, 343:1520-28.
15. Bruera E, Macmillan K, Hanson J, et al. 1989. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain, 39:13-16.
16. Budd K. 2003. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl, 133:9-14.
17. Burton AW, Driver LC, Mendoza TR, et al. 2004a. Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises. Clin J Pain, 20:195-97.
18. Burton AW, Rajagopal A, Shah HN, et al. 2004b. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med, 5:239-47.
19. Caraceni A, Zecca E, Bonezzi C, et al. 2004. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol, 22:2909-17.
20. Caraceni A, Zecca E, Martini C, et al. 1999. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage, 17:441-45.
21. Carr DB, Goudas LC, Balk EM, et al. 2004. Evidence report on the treatment of pain in cancer patients. J Nat Cancer Inst Monogri, 32:23-31.
22. Chapman SL, Byas-Smith MG, Reed BA. 2002. Effects of intermediate- and long-term use of opioids on cognition in patients with chronic pain. Clin J Pain, 18(Suppl 4):S83-90.
23. Cherny NJ. 2000. The management of cancer pain. CA Cancer J Clin, 50:70-116.
24. Collins SL, Moore RA, McQuay HJ, et al. 2000. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage, 20:449-58.
25. Coluzzi PH, Schwartzberg L, Conroy JD, et al. 2001. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain, 91:123-30.
26. Dalal S, Melzack R. 1998. Potentiation of opioid analgesia by psychostimulant drugs: a review. J Pain Symptom Manage, 16:245-53.
27. Davis MP, Walsh D. 2001. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer, 9:73-83.
28. Desmeules JA, Piguet V, Collart L, et al. 1996. Contribution of mono-aminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol, 41:7-12.
29. Dews TE, Mekhail N. 2004. Safe use of opioids in chronic noncancer pain. Cleve Clin J Med, 71:897-904.
30. Doggrell SA. 2004. Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs, 13:875-77.
31. Donnely S, Davis MP, Walsh D, et al. 2002. Morphine in cancer pain management: a practical guide. Support Care Cancer, 10:13-35.
32. Donner B, Zenz M, Strumpf M, et al. 1998. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage, 15:168-75.
33. Dunn MJ. 1984. Nonsteroidal anti-inflammatory drugs and renal function. Ann Rev Med, 35:411-28.
34. Dunteman ED. 2005. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother, 19:35-43.
35. Dworkin RH, Backonja M, Rowbotham MC, et al. 2003a. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol, 60:1524-34.
36. Dworkin RH, Corbin AE, Young JP, et al. 2003b. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology, 60:1274-83.
37. Eisenach JC, Du Pen S, Dubois M, et al. 1995. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain, 61:391-99.
38. Eisenberg E, Carr DB, Chalmers TC. 1995. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg, 80:290-95.
39. Erdine S, Talu GK. 1998. Cost effectiveness of implantable devices versus tunneled catheters. Curr Rev Pain, 2:157-62.
40. Ettinger AB, Portenoy RK. 1988. The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage, 3:99-103.
41. Evans HC, Easthope SE. 2003. Transdermal buprenotphine. Drugs, 63:1999-2010.
42. Farr WC. 1990. The use of corticosteroids for symptom management in terminally ill patients. Am J Hosp Care, 7:41-46.
43. Farrar JT, Cleary J, Rauck R, et al. 1998. Oral transmucosal fentanyl citrate: randomized, double blind placebo controlled trial for treatment of breakthrough pain in cancer patients. Anesth Analg, 89:732-38.
44. Fenstermaker RA. 1999. Neurosurgical invasive techniques for cancer pain: a pain specialist's view. Curr Pain Headache Rep, 6:190-97.
45. Finch PM, Roberts LJ, Price L, et al. 2000. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain, 16:251-54.
46. Fine PG, Busch MA. 1998. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage, 16:179-83.
47. Fourney DR, Schomer DF, Nader R, et al. 2003. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg, 98(Suppl 1):21-30.
48. Friedman LL, Rodgers PE. 2004. Pain management in palliative care. Clin Fam Pract, 6:371.
49. Fukshansky M, Are M, Burton AW. 2005. The role of opioids in cancer pain management. Pain Practice, 5:43-54.
50. Gatscher S, Becker R, Uhle E, et al. 2002. Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentation pain. Acta Neurochir Suppl (Wien), 79:75-76.
51. Gilmer-Hill HS, Boggan JE, Smith KA, et al. 1999. Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Surg Neurol, 51:12-15.
52. Glassman AH, Bigger JT. 1981. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatr, 38:815-20.
53. Gordon DH. 2005. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blinded, phase III trials. Clin Breast Cancer, 6:125-31.
54. Greenberg HS, Kim JH, Posner JB. 1980. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurology, 8:361-66.
55. Grond S, Radbruch L, Meuser T, et al. 1999. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage, 18:174-79.
56. Grond S, Zech D, Lebmann K, et al. 1997. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain, 69:191-98.
57. Gutstein HB, Akil H. 2001. Opioid analgesics. In: Hardman JG and Limbrid E (eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed, New York: McGraw-Hill Professional, pp. 569-619.
58. Haegerstam GAT. 2001. Pathophysiology of bone pain: A review. Acta Orthop Scand, 72:308-17.
59. Hagen NA, Thirlwell M, Eisenhoffer J, et al. 2005. Efficacy, safety, and steady-state pharmacokinetics of once-a-day oontrolled-release morphine (MSContinXL) in cancer pain. J Pain Symptom Manage, 29:80-90.
60. Harati Y, Gooch C, Swenson M, et al. 1998. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology, 50:1842-46.
61. Hassenbusch SJ, Gunes S, Wachsman S, et al. 2002. Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Med, 3:85-91.
62. Heiskanen TE, Ruismaki PM, Seppala TA, et al. 2000. Morphine or oxycodone in cancer pain? Acta Oncologica, 39:941-47.
63. van Hilten BJ, van de Beek WJ, Hoff JI, et al. 2000. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med, 343:625-30.
64. Hocking G, Cousins MJ 2003. Ketamine in chronic pain management: an evidence-based review. Anesth Analg, 97:1730-39.
65. Jacox A, Carr DB, Payne R, et al. 1994. Clinical practice guideline #9: Management of cancer pain [online]. (Publication #94-0592). AHCPR (Agency for Health Care Policy and Research). Washington, DC: Dept of Health and Human Services. Accessed 2 April 2006. URL: http://www.ahrq.gov/clinic/cpgarchv.htm.
66. Jemal A, Tiwari RC, Murray T, et al. 2004. Cancer Statistics, 2004. CA Cancer J Clin, 54:8-29.
67. Jensen TS. 2002. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain, 6A:61-8.
68. Jones B, Finlay I, Ray A, et al. 2003. Is there still a role for open cordotomy in cancer pain management? J Pain Symptom Manage, 25:179-84.
69. Kannan TR, Saxena A, Bhatnagar S, et al. 2002. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage, 23:60-5.
70. Kanpolat Y, Caglar S, Akyar S, et al. 1995. C7-guided pain procedures for intractable pain in malignancy. Acta Neurochir Suppl (Wien), 64:88-91.
71. Kao LW, Amin Y, Kirk MA, et al. 2003. Intrathecal baclofen withdrawal mimicking sepsis. J Emerg Med, 24:423-27.
72. Kedlaya D, Reynolds L, Waldman S. 2002. Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol, 16:651-65.
73. Khojainova N, Santiago-Palma J, Kornick CA, et al. 2002. Olanzapine in the management of cancer pain. J Pain Symptom Manage, 23:346-50.
74. Kornick CA, Santiago-Palma J, Moryl N, et al. 2003. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Safety, 26:951-73.
75. Korte W, Stoutz N, Morant R. 1996. Day-to-day titration to initiate transdermal fentanyl in cancerpatients: short- and long-term experience in a prospective study of 39 patients. J Pain Symptom Manage, 11:139-4.
76. Lawlor PG, Turner KS, Hanson J, et al. 1998. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer, 82:1167-73.
77. de Leon-Casasola OA, Kent E, Lema MJ. 1993. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer pain. Pain, 54:145-51.
78. Lordon SP. 2002. Interventional approach to cancer pain. Curr Pain Headache Rep, 6:202-6.
79. Lussier D, Huskey AG, Portenoy RK. 2004. Adjuvant analgesics in cancer pain management. The Oncologist, 9:571-91.
80. Lussier D, Pappagallo M. 2004. 10 most commonly asked questions about the use of opioids for chronic pain. The Neurologist, 10:221-24.
81. Lynch M. 2001. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci, 26:30-36.
82. Magni G, Arsie D, De Leo D. 1987. Antidepressants in the treatment of cancer pain: a survey in Italy. Pain, 29:347-53.
83. Maizels M, McCarberg B. 2005. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician, 71:483-90.
84. Mao J, Price DD, Mayer DJ. 1994. Thermal hyperalgesia in association with the developement of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci, 56:2301-12.
85. Mao J, Price DD, Mayer DJ. 1995. Mehcnisms of hyperalgesia and opiate tolerance: a current view of their possible interactions. Pain, 62:259-74.
86. Masand PS, Gupta S. 1999. Selective serotonin-reuptake inhibitors: an update. Harvard Rev Psychiatry, 52:547-52.
87. Mathur V. 2000. Ziconotide: a new pharmacological class of drug for the management of pain. Semin Anesth Periop Med Pain, 19:67-75.
88. McCarberg BH, Barkin RL. 2001. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther, 8:181-86.
89. McGivern JG, McDonough SI. 2004. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord, 3:457-78.
90. Meldrum M. 2005. The ladder and the clock: cancer pain and public policy at the end of the twentieth century. J Pain Symptom Manage, 29:41-54.
91. Mercandante S, Casuccio A, Genovese G. 1998. Ineffectiveness of dextromethorphan in cancer pain. J Pain Symptom Manage, 16:317-22.
92. Mercadante S. 1999a. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer, 86:1856-66.
93. Mercadante S. 1999b. Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Reg Anesth Pain Med, 24:74-83.
94. Mercadante S, Arcuri E, Tirelli W, et al. 2000. Analgesic effects of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage, 20:246-52.
95. Mercadante S, Fulfaro F, Casuccio A. 2001. The use of corticosteroids in home palliative care. Support Care Cancer, 9:386-89.
96. Merck. 2004. Merck announces voluntary worldwide withdrawal of VIOXX®. News release [online]. Accessed 2 April 2006. URL: http://www.vioxx.com/vioxx/documents/english/vioxx-press_release.pdf.
97. Miguel R. 2000. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control, 7:149-56.
98. Miljanich GP. 2004. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem, 11:3029-40.
99. Miljanich GP, Ramachandran J. 1995. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol, 35:707-34.
100. Mohammed I, Hussain A. 2004. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: A case report. BMC Clin Pharmacol, 4:1-5.
101. Morales E, Mucksavage JJ. 2002. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacotherapy, 22:1317-21.
102. Mukherjee D, Nissen SE, Topol EJ. 2001. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286:954-59.
103. Nauta HJ, Soukup VM, Fabian RH, et al. 2000. Punctate midline myelotomy for the relief of visceral cancer pain. J Neurosurg, 92(Suppl 2):125-30.
104. [NCCN] National Comprehensive Cancer Network. 2005. Cancer pain treatment guidelines for patients (version II) [online]. Accessed 4 April 2006. URL: http://www.nccn.org/patients/patient_gls.asp.
105. Nedeljkovic SS, Wasan A, Jamison RN. 2002. Assessment of efficacy of long-term opioid therapy in pain patients with substance abuse potential. Clin J Pain, 18(Suppl4):S39-51.
106. Noble B, Clark D, Meldrum M, et al. 2005. The measurement of pain, 1945-2000. J Pain Symptom Manage, 29:14-21.
107. Oneschuk D, al-Shahri MZ. 2003. The pattern of gabapentin use in a tertiary palliative care unit. J Palliat Care, 195:185-87.
108. Onghena P, van Houdenhove B. 1992. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain, 49:205-19.
109. Panchal SJ, Anghelescu DL, Benedetti C, et al. 2005. Adult cancer pain. Clinical Practice Guidelines in Oncology (version 2.2005) [online]. National Comprehensive Cancer Network. Accessed 6 April 2006. URL: http://www.nccn.org/professionals/cms/pdf/pain.pdf.
110. Payne R, Mathias SD, Pasta DJ, et al. 1998. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol, 16:1588-93.
111. Pereira J, Lawlor P, Vigano A, et al. 2001. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage, 22:672-87.
112. Pharo GH, Zhou L. 2005. Pharmacologic Management of Cancer Pain. JAOA, 105:S21-28.
113. Plancarte R, de Leon-Casasola OA, El-Helay M, et al. 1997. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth, 22:562-68.
114. Portenoy RK. 1996. Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage, 11:203-17.
115. Portenoy RK, Hagen NA. 1990. Breakthrough pain: definition, prevalence and characteristics. Pain, 41:273-82.
116. Price MJ. 2004. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain, 20:33-36.
117. Pud D, Eisenberg E, Spitzer A, et al. 1998. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo-controlled trial. Pain, 75:349-54.
118. Radbruch L, Sabatowski R, Petzke F, et al. 2001. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med, 15:309-21.
119. Raffit RB. 2001. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther, 26:257-64.
120. Raffa RB, Friderichs E, Reimann W, et al. 1992. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther, 260:275-85.
121. Rauck RL, Cherry D, Boyer MF, et al. 2003. Long-term intrathecal opioid therapy with a patient-activated implanted delivery system for the treatment of refractory cancer pain. J Pain, 4:441-47.
122. Rice AS, Maton S. 2001. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study. Pain, 94:215-24.
123. Rigoli G, Terrini G, Cordioli Z. Intrathecal baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: A report of 2 cases. Arch Phys Med Rehabil, 85:2064-66.
124. Ripamonti C, Groff L, Brunelli C, et al. 1998. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol, 16:3216-21.
125. Rosen LS, Gordon D, Kaminski M, et al. 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7:377-87.
126. Roth A, Kolaric K. 1986. Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer: results of a controlled randomized study. Oncology, 43:283-87.
127. Rouff G, Lema M. 2003. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage, 25(Suppl 2):S21-31.
128. Rowbotham M, Harden N, Stacey B, et al. 1998. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA, 280:1837-42.
129. Rozans M, Dreisbach A, Lertora JJ, et al. 2002. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol, 20:335-39.
130. Russell IJ, Kamin M, Bennett RM, et al. 2000. Eficacy of tramadol in treatment of pain in fbromyalgia. J Clin Rheumatol, 6:250-57.
131. Saarto T, Wiffen PJ. 2005. Antidepressants for neuropathic pain. Cochrane Database Syst Rev, 3:CD005454.
132. Sarhill N, Walsh D, Nelson KA. 2001. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer, 9:84-96.
133. Schug SA, Zech D, Dorr U. 1990. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage, 5:27-32.
134. Serafini AN. 2001. Therapy of metastatic bone pain. J Nucl Med, 42:895-906.
135. Shah HN, Burton AW, Mendoza T, et al. 2003. Neurolytic blockade of the splanchnic nerves block relieves refi-actory pain associated with upper abdominal malignancy. Annual Meeting of the American Society of Anesthesiologists. October 11-15, San Francisco, California: Abstract A1024.
136. Sindrup SH, Bach FW, Madsen C, et al. 2003. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology, 60:1284-89.
137. Sindrup SH, Bjerre U, Dejgaard A, et al. 1992. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther, 52:547-52.
138. Sindrup SH, Gram LF, Brosen K, et al. 1990. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain, 42:135-44.
139. Singh D. 2004. Merck withdraws arthritis drug worldwide. BMJ, 329:816.
140. Skaer TL. 2004. Practice guidelines for transdermal opioids in malignant pain. Drugs, 64:2629-38.
141. Slavin KV, Hsu FPK, Fessler RG. 2002. Intrathecal opioids: intrathecal drug-delivery systems. In: Burchiel KJ (ed). Surgical management of pain. New York: Thieme, pp 603-13.
142. Slavin KV, Solko AM. 2003. Intrathecal narcotics: spinal and intraventricular. In: Schulder (ed). Handbook of stereotactic and functional neurosurgery. New York: Marcel Dekker, pp 443-57.
143. Slavin KV, Tesoro EP, Mucksavage JJ. 2004. The treatment of cancer pain. Drugs Today (Barc.), 40:235-45.
144. Smith TJ, Staats PS, Deer T, et al. 2002. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol, 20:4040-49.
145. Staats PS, Yearwood T, Charapata S, et al. 2004. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA, 291:63-70.
146. Szanto J, Ady N, Jozsef S. 1992. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology, 49:180-82.
147. Taub E. 2003. Spinal cord stimulation for cancer-related pain: a neglected indication? Quadrennial Meeting Am Soc Stereotactic Funct Neurosurg. May 18-21, New York: Abstract 52.
148. Tremont-Lukats IW, Megeff C, Backonja MM. 2000. Anticonvulsants for neuropathic pam syndromes: mechanism of action and place in therapy. Drugs, 60:1029-52.
149. Trujillo KA, Akil H. 1991. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 251:85-7.
150. Turk DC, Monarch ES, Williams AD. 2002. Cancer patients in pain: considerations for assessing the whole person. Rematol Oncol Clin North Am, 16:511-25.
151. Valdimarsdottir U, Helgason AR, Furst CJ, et al. 2002. The unrecognized cost of cancer patients' unrelieved symptoms: a nationwide follow-up of their surviving partners. Br J Cancer, 86:1540-45.
152. Varvel JR, Shafer SL, Hwang SS, et al. 1989. Absorption characteristics of transdermally administered fentanyl. Anesthesiology, 70:928-34.
153. Vestergaard K, Andersen G, Gottrup H, et al. 2001. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology, 56:184-90.
154. Vielhaber A, Portenoy RK. 2002. Advances in cancer pain management. Hematol Oncol Clin North Am, 16:527-41.
155. Walsh TD. 1986. Controlled study of imipramine and morphine in chronic pain due to advanced cancer. Proc Am Soc Clin Oncol, 5:237.
156. Watanabe S, Bruera E. 1994. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage, 9:442-45.
157. Watson CP. 2000. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain, 16(Suppl 2):49-55.
158. Webster L, Henderson R, Katz N, et al. 2001. Characterization of confusion, an adverse event associated with intrathecal ziconotide infilsion in chronic pain patients. Pain Med, 2:253-54.
159. Weinbroum AA, Bender B, Nirkin A, et al. 2004. Dextromethorphan-associated epidural patient-controlled analgesia provides better pain- and analgesics-sparing effects than dextromethorphan-associated intravenous patient-controlled analgesia after bone-malignancy resection: a randomized, placebo-controlled, double-blinded study. Anesth Analg, 98:714-22.
160. Wermeling D, Drass M, Ellis D, et al. 2003. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol, 43:624-36.
161. Whittle IR, Jenkinson JL. 1995. CT-guided stereotactic antero-medial pulvinotomy and centromedian-parafascicular thalamotomy for intractable malignant pain. Br J Neurosurg, 9:195-200.
162. Wilson PR, Caplan RA, Connis RT, et al. 1997. Practice guidelines for chronic pain management: a report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Anesthesiology, 86:995-1004.
163. Winslow M, Seymour J, Clark D. 2005. Stories of cancer pain: a historical perspective. J Pain Symptom Manage, 29:22-31.
164. Wong DL, Baker CM. 1988. Pain in children: comparison of assessment scales. Pediatr Nurs, 14:9-17.
165. Wong ET, Gunes S, Guaghan E, et al. 1997. Palliation of intractable cancer pain by MRI-guided cingulotomy. Clin J Pain, 13:260-63.
166. Yajnik S, Singh GP, Singh G, et al. 1992. Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage, 7:209-30.
167. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. 1997. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain, 73:223-30.
168. Zech DF, Grond S, Lynch J, et al. 1995. Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain, 63:65-76.